The global oncologic cancers testing sector is exhibiting significant expansion, propelled by a rising prevalence of leukemia and other related diseases. Analysts estimate the current market value to be substantial, with projections indicating a steady compound annual increase rate (CAGR) over the coming period. Key drivers shaping the landscape in